QHSLab Inc. (OTCMKTS:USAQ) Celebrates NSF Invitation for AIR-GUIDDE Technology Development

QHSLab Inc. recently disclosed that it has been invited by the National Science Foundation (NSF) to submit an application for the Airway Instantaneous Regional Guided Interface for Drug Delivery Efficiency (AIR-GUIDDE) technology. This exclusive invitation, part of the NSF Small Business Technology Transfer (STTR) program, signifies the innovative potential of the project.

The company announced this significant milestone in a press release on December 13, 2024. The collaboration between QHSLab Inc. and South Dakota State University (SDSU) has received recognition from the NSF, showcasing the advanced scientific principles and potential impact of the AIR-GUIDDE platform.

The AIR-GUIDDE technology aims to revolutionize drug development by providing real-time insights into drug deposition patterns within respiratory and nasal systems. This innovation is expected to streamline development processes, reduce costs, and enhance the precision of drug delivery for various medical conditions including asthma, COPD, influenza, and other viral threats.

Saikat Basu, Assistant Professor of Mechanical Engineering at SDSU and Principal Investigator of AIR-GUIDDE, emphasized the groundbreaking nature of the project, highlighting its potential to improve patient outcomes and lower healthcare costs significantly.

The partnership with SDSU and the NSF recognition aligns with QHSLab’s focus on driving innovation and growth in the healthcare sector. Marcos Sanchez-Gonzalez, MD, PhD, Vice President of Medical and Scientific Affairs at QHSLab, emphasized how AIR-GUIDDE complements the company’s existing digital medicine platforms, positioning it as a leader in incorporating cutting-edge research into practical healthcare applications.

The NSF’s invitation for funding further validates QHSLab’s expertise and strategic vision, providing the company with opportunities for impactful collaborations and expanding its portfolio of revenue-generating technologies. The financial support from the NSF STTR program will accelerate the development and commercialization of AIR-GUIDDE, enabling QHSLab to bring this transformative platform to market efficiently.

QHSLab’s CEO, Troy Grogan, highlighted the significance of the NSF invitation, viewing it as a testament to the company’s commitment to innovation and growth. This initiative resonates with QHSLab’s mission and growth strategy, showcasing the versatility of its platforms and presenting sustainable revenue opportunities.

For more information about QHSLab and its healthcare solutions, interested parties can visit the company’s website at www.qhslab.com. Investors and stakeholders are encouraged to follow QHSLab on various social media channels, including Twitter, LinkedIn, Facebook, and Instagram, for the latest updates and disclosures.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read QHSLab’s 8K filing here.

QHSLab Company Profile

QHSLab, Inc, a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine.